CIK 0001829802
- Emerging growth company
Faeth Therapeutics, Inc.
Sign in to watch- Ticker
- FTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 512-200-2982
- Business address
- 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
- Former names
- Sensei Biotherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 12 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-01 | Cambrian BioPharma Inc 10% owner | Purchase | +2,458 | $3.60 | $9K | 5,230,786 |
| 2022-02-28 | Peyer James Director | Purchase | +42 | $3.60 | $151 | 5,228,328 |
| 2022-02-28 | Cambrian BioPharma Inc 10% owner | Purchase | +42 | $3.60 | $151 | 5,228,328 |
| 2022-02-25 | Peyer James Director | Purchase | +2,500 | $3.65 | $9K | 5,228,286 |
| 2022-02-25 | Cambrian BioPharma Inc 10% owner | Purchase | +2,500 | $3.65 | $9K | 5,228,286 |
| 2022-02-24 | Cambrian BioPharma Inc 10% owner | Purchase | +15,000 | $3.63 | $54K | 5,225,786 |
| 2022-02-24 | Peyer James Director | Purchase | +15,000 | $3.63 | $54K | 5,225,786 |
| 2022-02-23 | Cambrian BioPharma Inc 10% owner | Purchase | +2,500 | $3.80 | $10K | 5,210,786 |
| 2022-02-23 | Peyer James Director | Purchase | +2,500 | $3.80 | $10K | 5,210,786 |
| 2022-02-18 | Peyer James Director | Purchase | +15,000 | $3.97 | $60K | 5,208,286 |
| 2022-02-18 | Cambrian BioPharma Inc 10% owner | Purchase | +15,000 | $3.97 | $60K | 5,208,286 |
| 2022-02-17 | Peyer James Director | Purchase | +4,949 | $4.17 | $21K | 5,193,286 |
| 2022-02-17 | Cambrian BioPharma Inc 10% owner | Purchase | +4,949 | $4.17 | $21K | 5,193,286 |
| 2022-02-16 | Cambrian BioPharma Inc 10% owner | Purchase | +2,551 | $4.25 | $11K | 5,188,337 |
| 2022-02-16 | Peyer James Director | Purchase | +2,551 | $4.25 | $11K | 5,188,337 |
| 2022-02-15 | Pierce Robert Hamilton Chief R&D Officer | Grant or award | +21,000 | 21,000 | ||
| 2022-02-15 | Pierce Robert Hamilton Chief R&D Officer | Grant or award · Stock Option (Right to Buy) | +62,000 | 62,000 | ||
| 2022-02-15 | Colgan Erin Chief Financial Officer | Grant or award | +21,000 | 21,686 | ||
| 2022-02-15 | Colgan Erin Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +62,000 | 62,000 | ||
| 2022-02-15 | Celebi John President and CEO | Grant or award | +53,900 | 54,114 |
Page 13 of 20 · 385 trades